Clinical Trial Update: Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating chemotherapy plus the Bcl-xL inhibitor AT-101 for organ preservation in adults with advanced laryngeal cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Laryngeal Cancer

Drugs mentioned

• AT-101 (gossypol acetic acid)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Laryngeal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-07-20